Localized Darier Disease Resistant to Topical Fluorouracil: What to Do Next
Clinical Scenario
This protocol is for patients with Darier disease whose skin lesions are localized — not disseminated or generalized. When initial topical therapy fails to produce the expected degree of lesion control, a structured next-line approach is needed. The clinical goal is marked improvement and near resolution of lesions, or sustained remission.
Prior Treatment — Goal Not Achieved
The preceding line used topical fluorouracil (5-FU) for severe and resistant localized Darier disease lesions. The expected outcome — marked improvement and resolution of lesions within the defined treatment window — was not reached, making escalation to this protocol appropriate.
Next-Line Approach (partial — full regimen in protocol)
This line introduces alternative topical agents from different pharmacological classes that have demonstrated meaningful lesion responses in localized Darier disease resistant to prior topical therapy. The approach targets marked improvement and near resolution of lesions, with durable remission as the endpoint.
The complete protocol — including agent selection, duration, and clinical monitoring — is available via the link below.
References
DOI: 10.25259/IJDVL_963_19
For localized and resistant skin lesions, physical therapies including surgical excision, dermabrasion and CO2 laser ablation were the first line choices.
Diclofenac sodium 3% was used twice a day in 3 patients for 3 to 8 months with marked improvement and near resolution of all the lesions.
Tacalcitol was used in a 39‑year‑old female with substantial improvement and no relapse after 5 months.
Tacrolimus 0.1% was used twice a day in a 22‑year‑old female with remission after 8 weeks and no relapse for up to 1 year after the treatment.
View source ↗